US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Merck & Co., Inc.

MRKNYSE

93.55

USD
+1.46
(+1.59%)
Market Closed
16.74P/E
13Forward P/E
0.65P/E to S&P500
236.570BMarket CAP
2.87%Div Yield

Merck & Co., Inc.

NYSE:MRK

RECENT
PRICE

93.55

P/E
RATIO

16.74

(PEG:0.20)

P/E RATIO
RELATIVE
TO S&P

0.65

DIV
YLD

3.26%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

- - Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

Fiscal year

10.02

2.11

2.82

1.52

10.39

2.04

2.66

1.53

11.15

1.51

2.76

1.52

11.17

3.66

2.47

1.54

13.01

6.12

0.92

1.65

14.86

0.28

2.95

1.57

15.80

2.06

3.51

1.58

15.62

2.04

2.67

1.73

15.04

1.50

3.45

1.80

14.88

4.20

1.95

1.85

14.20

1.60

4.00

1.84

14.48

1.43

3.19

1.86

14.88

0.89

1.69

1.92

16.31

2.40

3.20

1.99

18.45

3.88

3.93

2.24

18.97

2.79

2.20

2.46

19.25

5.16

3.82

2.61

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.64

8.16

0.45

8.06

0.47

8.38

0.61

8.78

0.69

28.01

0.54

17.57

0.57

17.93

0.65

17.52

0.53

17.00

0.82

17.14

0.46

16.06

0.59

14.58

0.70

12.73

1.01

10.30

1.37

10.20

1.85

10.01

1.76

15.09

CAPEX per share

Book Value per share

2,197

2,178

2,171

2,136

2,109

3,095

3,041

3,027

2,928

2,838

2,781

2,749

2,697

2,593

2,539

2,530

2,530

Comm.Shares outs.(m)

- -

- -

- -

18.0

0.99

4.17%

32.0

1.85

3.15%

9.6

0.45

4.39%

4.6

0.06

5.90%

123.7

5.97

4.56%

15.8

0.97

4.84%

19.4

1.30

4.39%

29.4

1.73

4.08%

13.0

0.72

3.39%

33.6

1.68

3.42%

38.2

1.72

3.42%

66.5

2.82

3.24%

25.5

1.02

3.26%

20.2

0.83

2.87%

27.5

0.73

3.20%

14.7

0.49

3.44%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/12/21 | Q4)

Total liabilities
$67,437 m.

Total assets
$105,694 m.

Long-term debt
$30,690 m.

Cash and equiv.
$8,096 m.

Goodwill $21,264 m.

Retained earnings $53,696 m.

Common stock 2,527 m. shares

Market Capitalisation
$236,570 m. (as of 21/5/22)

45,987

7.3%

48,047

18.7%

47,267

20.9%

44,033

17.4%

42,237

15.8%

39,498

19.1%

39,807

15.1%

40,122

18.2%

42,294

21.1%

46,840

26.1%

47,994

17.7%

48,704

27.1%

Revenue (m)

Operating margin

7,381

861

7,427

6,272

6,978

6,168

6,988

4,404

6,691

11,920

6,375

4,442

5,441

3,920

4,637

2,394

4,519

6,220

3,652

9,843

3,625

7,067

3,214

13,049

Depreciation (m)

Net profit (m)

40.6%

1.9%

12.8%

13.1%

27.9%

13.0%

18.5%

10.0%

30.9%

28.2%

17.4%

11.2%

15.4%

9.8%

62.9%

6.0%

28.8%

14.7%

14.7%

21.0%

19.4%

14.7%

11.0%

26.8%

Income tax rate

Net profit margin

13,423

15,482

54,376

16,936

15,525

54,517

16,509

16,254

53,020

17,817

20,539

49,765

14,407

18,699

48,647

10,561

23,929

44,676

13,410

24,274

40,088

6,152

21,353

34,336

3,669

19,806

26,701

5,263

22,736

25,907

437

25,360

25,317

6,394

30,690

38,184

Working capital (m)

Long-term debt (m)

Equity (m)

1.5%

2.2%

1.6%

8.0%

7.8%

11.5%

7.9%

9.0%

11.6%

6.0%

6.0%

8.8%

15.6%

18.3%

24.5%

6.1%

6.0%

9.9%

5.8%

5.6%

9.8%

3.9%

8.3%

7.0%

11.2%

11.5%

23.3%

17.1%

14.7%

38.0%

12.1%

10.5%

27.9%

16.7%

14.6%

34.2%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

10,450

8,836

8,870

Receivables

6,778

7,851

9,230

Inventory

5,978

6,310

5,953

Other

4,277

4,756

6,987

Current assets

27,483

27,764

30,266

Acc. Payable

3,738

4,594

4,609

Debt due

3,610

6,431

2,412

Other

14,872

16,302

16,851

Current liab.

22,220

27,327

23,872

73.0%

180.1%

(463.6)%

70.5%

23.3%

63.2%

15.1%

97.0%

(19.8)%

116.7%

56.0%

233.6%

(15.2)%

83.5%

(30.7)%

97.7%

(115.8)%

201.4%

16.8%

171.7%

42.1%

105.1%

12.1%

134.6%

Plowback ratio

Div.&Repurch. to FCF

Merck & Co., Inc. (US) started trading on June 6, 1946 (cik: 0000310158), operates in the Healthcare sector (Drug Manufacturers—General industry), has 67,000 full-time employees, and is led by Mr. Kenneth Frazier. Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

5.03%

0.47%

Cash flow

32.89%

15.92%

Earnings

68.63%

33.68%

Dividends

6.42%

2.71%

Book value

5.83%

-1.98%

Insider trading

Type

Shares

Date

Oosthuizen Johannes Jacobus

Award

21,359

05/04/22

Oosthuizen Johannes Jacobus

Exempt

907

05/04/22

Oosthuizen Johannes Jacobus

InKind

447

05/04/22

Oosthuizen Johannes Jacobus

Exempt

907

05/04/22

Karachun Rita A

Exempt

949

05/04/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2019

10,816

11,760

12,397

11,868

46,841

2020

12,057

10,872

12,551

12,515

47,995

2021

12,080

11,402

13,154

13,521

50,157

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2019

1.15

1.05

0.75

0.93

3.88

2020

1.27

1.19

1.16

(0.83)

2.79

2021

1.26

0.61

1.81

1.49

5.16

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2019

0.56

0.58

0.55

0.55

2.24

2020

0.61

0.62

0.61

0.61

2.46

2021

0.65

0.66

0.65

0.65

2.61

03/14/2022

Merck’s Covid-19 Pill Heavily Used So Far Despite Concerns

The Wall Street Journal - Read more...

02/03/2022

Merck, Eli Lilly Covid-19 Treatments Power Quarterly Sales Gains

The Wall Street Journal - Read more...

02/03/2022

Meta, Amazon, Snap, Pinterest: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

01/28/2022

Merck’s Covid-19 Pill Shows Promise Against Omicron

The Wall Street Journal - Read more...

01/07/2022

GameStop, AMC, DraftKings, Starbucks: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/23/2021

FDA Authorizes Merck’s Covid-19 Pill for At-Home Treatment

The Wall Street Journal - Read more...

12/01/2021

Salesforce, Snowflake, Zscaler, Box: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/30/2021

Omicron Variant Sends Policy Makers Scrambling as Science Lags Behind

The Wall Street Journal - Read more...

11/30/2021

Peloton, Moderna, Marriott, Pfizer: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/29/2021

Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/26/2021

Merck’s Covid-19 Pill Was 30% Effective in Final Analysis

The Wall Street Journal - Read more...

11/08/2021

Tesla, Coinbase, Merck: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

11/04/2021

Tesla, Moderna, Zillow, Qualcomm, Qorvo: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/04/2021

Merck Covid-19 Pill Cleared for Use in U.K., Its First Authorization

The Wall Street Journal - Read more...

10/28/2021

Shiba Inu Coin, Tesla, Ford, Nokia: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/27/2021

Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply

The Wall Street Journal - Read more...

10/12/2021

Airbnb, Merck, High Tide, Square: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/11/2021

Merck Asks FDA to Authorize Promising Covid-19 Pill

The Wall Street Journal - Read more...

10/11/2021

Marathon Digital, Occidental, Southwest: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

10/04/2021

Tesla, Merck, Moderna: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

10/01/2021

Merck Pill Intended to Treat Covid-19 Succeeds in Key Study

The Wall Street Journal - Read more...

10/01/2021

AMC, Bitcoin, Lordstown, Merck: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

09/30/2021

Merck to Buy Acceleron Pharma for $11.5 Billion

The Wall Street Journal - Read more...

09/30/2021

Virgin Galactic, Camber Energy, Bed Bath & Beyond, Jefferies: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

09/28/2021

Facebook, Ford, Acceleron Pharma: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

09/27/2021

Merck Nears Deal to Acquire Acceleron Pharma

The Wall Street Journal - Read more...

07/25/2021

Race for Covid-19 Pill Heats Up

The Wall Street Journal - Read more...

04/29/2021

Facebook, Twitter, eBay, Apple: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

03/24/2021

Merck Names 30-Year Company Veteran as CFO

The Wall Street Journal - Read more...

03/15/2021

Gilead and Merck Join Forces to Develop Long-Acting HIV Treatment

The Wall Street Journal - Read more...

03/07/2021

U.S. Scientists Question Single Dose for Pfizer, Moderna Shots

The Wall Street Journal - Read more...

03/03/2021

Biden Says U.S. to Have Vaccines for All Adults by End of May

The Wall Street Journal - Read more...

02/05/2021

Merck CFO Brings Corporate Strategy Experience to CEO Role

The Wall Street Journal - Read more...

02/04/2021

Merck’s Kenneth Frazier to Retire as CEO

The Wall Street Journal - Read more...

01/25/2021

Merck Scraps Covid Vaccine Candidates

The Wall Street Journal - Read more...

01/25/2021

GameStop, BlackBerry, Moderna: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

01/06/2021

CEOs Ponder Holding Back Campaign Money

The Wall Street Journal - Read more...

11/23/2020

Merck to Buy OncoImmune for $425 Million Amid Race for Covid-19 Treatments

The Wall Street Journal - Read more...

10/23/2020

Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase

The Wall Street Journal - Read more...

10/02/2020

Merck’s R&D Chief to Retire

The Wall Street Journal - Read more...

09/14/2020

Merck to Invest $1 Billion in Seattle Genetics

The Wall Street Journal - Read more...

09/11/2020

Merck Covid-19 Vaccine Begins Human Testing

The Wall Street Journal - Read more...